Related Experiment Video
Updated: Aug 19, 2026

A High-Throughput Comet Assay Approach for Assessing Cellular DNA Damage
Published on: May 10, 2022
BLM helicase is activated in BCR/ABL leukemia cells to modulate responses to cisplatin
Artur Slupianek1, Ewa Gurdek, Mateusz Koptyra
1Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.
Abstract:
Bloom protein (BLM) is a 3'-5' helicase, mutated in Bloom syndrome, which plays an important role in response to DNA double-strand breaks and stalled replication forks. Here, we show that BCR/ABL tyrosine kinase, which also modulates DNA repair capacity, is associated with elevated expression of BLM. Downregulation of BLM by antisense cDNA or dominant-negative mutant inhibits homologous recombination repair (HRR) and increases sensitivity to cisplatin in BCR/ABL-positive cells. Bone marrow cells from mice heterozygous for BLM mutation, BLM(Cin/+), transfected with BCR/ABL display increased sensitivity to cisplatin compared to those obtained from the wild-type littermates. BCR/ABL promotes interactions of BLM with RAD51, while simultaneous overexpression of BLM and RAD51 in normal cells increases drug resistance. These data suggest that BLM collaborates with RAD51 to facilitate HRR and promotes the resistance of BCR/ABL-positive leukemia cells to DNA-damaging agents.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Abnormal Proliferation
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Induced Pluripotent Stem Cells
Somatic cells are...